Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab”by Graser et al
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/6/e012582.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849431018498424832 |
|---|---|
| author | Liwen Zhang Mingzhu Gao Jinyou Wang |
| author_facet | Liwen Zhang Mingzhu Gao Jinyou Wang |
| author_sort | Liwen Zhang |
| collection | DOAJ |
| format | Article |
| id | doaj-art-144811bc342c40f5a739ca7bf7c53cf6 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-144811bc342c40f5a739ca7bf7c53cf62025-08-20T03:27:47ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-06-0113610.1136/jitc-2025-012582Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab”by Graser et alLiwen Zhang0Mingzhu Gao1Jinyou Wang2Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, ChinaDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, ChinaDepartment of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, Chinahttps://jitc.bmj.com/content/13/6/e012582.full |
| spellingShingle | Liwen Zhang Mingzhu Gao Jinyou Wang Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab”by Graser et al Journal for ImmunoTherapy of Cancer |
| title | Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab”by Graser et al |
| title_full | Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab”by Graser et al |
| title_fullStr | Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab”by Graser et al |
| title_full_unstemmed | Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab”by Graser et al |
| title_short | Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab”by Graser et al |
| title_sort | correspondence on early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab by graser et al |
| url | https://jitc.bmj.com/content/13/6/e012582.full |
| work_keys_str_mv | AT liwenzhang correspondenceonearlydynamicsofclinicalandlaboratoryparameterspredictprimaryrefractorydiseaseinpatientswithmetastaticurothelialcarcinomareceivingatezolizumabbygraseretal AT mingzhugao correspondenceonearlydynamicsofclinicalandlaboratoryparameterspredictprimaryrefractorydiseaseinpatientswithmetastaticurothelialcarcinomareceivingatezolizumabbygraseretal AT jinyouwang correspondenceonearlydynamicsofclinicalandlaboratoryparameterspredictprimaryrefractorydiseaseinpatientswithmetastaticurothelialcarcinomareceivingatezolizumabbygraseretal |